MyJournals.org - Science - Pharmaceuticals, Vol. 16, Pages 492: Effects of Apocynin, a NADPH Oxidase Inhibitor, in the Protection of the Heart from Ischemia/Reperfusion Injury (Pharmaceuticals)
Ocugen Establishes Vaccine Scientific Advisory Board
mychesco.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mychesco.com Daily Mail and Mail on Sunday newspapers.
Ocugen Establishes Vaccine Scientific Advisory Board – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Published: Dec 23, 2020
MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies, today announced the appointment of a vaccine scientific advisory board comprised of leading academic and industry experts in the vaccine field to evaluate the clinical and regulatory path to approval in the US market of Bharat Biotech’s COVAXIN™, a whole-virion inactivated COVID-19 vaccine candidate to be co-developed by Ocugen and Bharat Biotech for the US market.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen remarked, “We are thrilled to welcome this group of esteemed thought leaders to the Ocugen team to assist in our co-development with Bharat Biotech of COVAXIN™. This unique yet traditional vaccine candidate is different from other options currently available in the US market with potentially broader coverage against multip